Palisade Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $257.9M
- Price
- $1.48
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.67%
- Volume
- 825.2K
About
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Quick stats
Shares outstanding174.3M
Computed float173.3M
Float / shares99.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001357459
Websitehttps://www.palisadebio.com
AI Summary
AI-generated1/25
minorbullishclinical trial
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Palisade Bio's lead program PALI-2108 will be featured in four presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in Barcelona.
The lineup includes an oral presentation of Phase 1b findings in fibrostenotic Crohn's disease showing early endoscopic improvement and PDE4 target engagement, plus three moderated posters covering gut-targeted exposure, rapid clinical response in ulcerative colitis, and a response-predicting biomarker.
PALI-2108 is being advanced into Phase 2 trials in both ulcerative colitis and Crohn's disease as a once-daily oral PDE4 inhibitor prodrug.